US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

35.86

+0.27000.76%

Post-market: 35.860.00000.00%19:30 EDT

Volume:174.97K

Turnover:6.28M

Market Cap:3.10B

PE:5.80

High:36.10

Open:35.58

Low:35.39

Close:35.59

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.87

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.45

PE(LYR):64.61

Loading ...

Overview Company News Filings

A New "Dark Horse" Ingredient Emerges in the Sensitive Skin Market

Array Digital Infrastructure Inc expected to post earnings of 86 cents a share - Earnings Preview

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Did Proposed Officer Liability Shield Just Shift Array Digital Infrastructure's (AD) Investment Narrative?

Simply Wall St.

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

TDS publishes 2025 annual report after UScellular wireless sale to T-Mobile

Digitus Group Signs Agreement To Acquire Gulfsat Kuwait

Array Digital Infrastructure announces annual shareholder meeting

Array Digital Infrastructure publishes 2025 annual report after wireless divestiture transition

Press Release: AC Immune Announces Amendment to Morphomer (R) Tau License and Collaboration Agreement with Lilly

RBC Capital Keeps Their Buy Rating on Array Digital Infrastructure (AD)

Blockchain Digital Infrastructure FY25 net loss narrows to $0.8 million; revenue falls 19% to $19 million

Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Annovis Publishes Historical Review of Buntanetap in The Scientist

Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?

Simply Wall St.

Press Release: INmune Bio Inc. Announces 2025 Results and Provides Business Update

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/AD/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":35.86,"timestamp":1787688000000,"preClose":35.59,"halted":0,"volume":174970,"hourTrading":{"tag":"盘后","latestPrice":35.86,"preClose":35.86,"latestTime":"19:30 EDT","volume":587,"amount":21049.82,"timestamp":1787700601509,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007586400674346614,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Not Yet Opened","change":0.27,"latestTime":"08-25 16:00:00 EDT","open":35.58,"high":36.1,"low":35.39,"amount":6279990.87055,"amplitude":0.019949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":35.59,"postHourTrading":{"tag":"盘后","latestPrice":35.86,"preClose":35.86,"latestTime":"19:30 EDT","volume":587,"amount":21049.82,"timestamp":1787700601509,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.872417,"impliedVol":0.2103,"impliedVolPercentile":0.136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.872417,"shares":86379877,"dividePrice":0,"high":36.1,"amplitude":0.019949,"preClose":35.59,"low":35.39,"week52Low":33.71,"pbRate":"2.45","psRate":"14.51","week52High":60.82,"institutionHeld":0.3649,"latestPrice":35.86,"eps":6.185934,"divideRate":0,"volume":174970,"delay":0,"ttmEps":6.185934,"open":35.58,"prevYearClose":53.62,"prevWeekClose":35.66,"prevMonthClose":34.84,"prevQuarterClose":36.26,"fiveDayClose":35.05,"twentyDayClose":35,"sixtyDayClose":50.86,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-08-24","current":5.797023,"percent":0.272374,"low":-273.92211,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"high":320.844562,"avg":59.893555,"sd":173.763323,"marketCap":3083841140},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-24","current":5.758764,"twenty":-175.810243,"median":21.467154,"eighty":260.571771,"marketCap":3083841140}],"updateTime":1787693235089},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143748834","title":"A New \"Dark Horse\" Ingredient Emerges in the Sensitive Skin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1143748834","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143748834?lang=en_us&edition=fundamental","pubTime":"2026-04-27 22:52","pubTimestamp":1777301534,"startTime":"0","endTime":"0","summary":"The Chinese cosmetics industry has seen numerous narratives centered around ingredients over the past few years. From traditional botanical extracts to synthetic biology, a range of \"Chinese...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630276188","title":"Array Digital Infrastructure Inc  expected to post earnings of 86 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2630276188","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630276188?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:32","pubTimestamp":1777062739,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc  expected to post earnings of86cents a share - Earnings Preview Array Digital Infrastructure Inc AD.N, AD is expected to  show a fall in quarterly revenue when it repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL8N4172JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","AD","LU0795875086.SGD","LU0314104364.USD","BK4504","LU0882574139.USD","LU1720051017.SGD","BK4127","LU1244550577.SGD","LU2028103732.USD","LU0795875169.SGD","BK4534","LU1989772923.USD","IE00BKVL7J92.USD","BK4132","LU1732799900.SGD","LU2023251221.USD","BK4199","LU2271345857.HKD","SLE","LU1074936037.SGD","LU2347655156.SGD","BK4588","LU1162221912.USD","LU1244550221.USD","LU0971096721.USD","LU0234570918.USD","BK4581","LU0006306889.USD","LU0106831901.USD","LU0158827781.USD","IBD","ITP","LU2357305700.SGD","BK4585","LU2089284900.SGD","LU0320765646.SGD","LU0158827948.USD","LU1244550494.USD","BK4516","LU2133065610.SGD","LU2089283258.USD","BK4077","LU0557290698.USD","LU0912757837.SGD","LU0106261372.USD","LU2111349929.HKD","LU0528227936.USD","LU0225283273.USD","LU1791710400.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629583294","title":"CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2629583294","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629583294?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:59","pubTimestamp":1776949140,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, April  23, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279998/0/en/CMS-867-HK-8A8-SG-NDA-for-the-Seasonal-Allergic-Rhinitis-Indication-of-Class-1-Innovative-Drug-MG-K10-Accepted-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAR","LU0553294199.USD","BK4123","BK4588","LU2346227817.USD","BK4132","MG","AD","LU0545039389.USD","LU0949170772.SGD","IE00B66KJ199.SGD","BK4208","BK4135","LU0738911758.USD","IE00B7SZL793.SGD","LU2500361329.USD","LU0661504455.SGD","BK4585","CMS","LU2637428348.USD","LU1003077747.HKD","IE0031619046.USD","LU1894683264.USD","IE00B19Z4B17.USD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629010016","title":"Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”","url":"https://stock-news.laohu8.com/highlight/detail?id=2629010016","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629010016?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s DiseaseNEWARK, N.J","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/Rafael-Holdings-Announces-Patent-Licensing-Agreement-with-MIT-for-Small-Molecules-to-Improve-Myelination-in-ApoE4-positive-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["API","BK4135","RFL","AD","BK4132","BK4205","BK4503","BK4551","BK4535","MIT","BK4233","CNS","BK4007","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629743778","title":"Did Proposed Officer Liability Shield Just Shift Array Digital Infrastructure's (AD) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629743778","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629743778?lang=en_us&edition=fundamental","pubTime":"2026-04-21 01:04","pubTimestamp":1776704670,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure, Inc. has proposed amending its Restated Certificate of Incorporation to add exculpation protections for certain corporate officers against monetary damages for breaches of the fiduciary duty of care, subject to limitations, with shareholders asked to vote on the change at the May 19, 2026 annual meeting.\nThis move, which would extend protections similar to those already available to directors, raises important questions about how investors assess management...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/did-proposed-officer-liability-shield-just-shift-array-digit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/did-proposed-officer-liability-shield-just-shift-array-digit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DTCR","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4202","AD","AS","BK4017","ZK","LU1223082519.USD","LU1223082196.USD","BK7050","BK4132","BK4099","LU1223083913.SGD","CDE","CDE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626874261","title":"Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2626874261","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626874261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:30","pubTimestamp":1775737800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4139","BK4132","LU1169589451.USD","LU1169590202.USD","ANVS","BK4023","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626923789","title":"TDS publishes 2025 annual report after UScellular wireless sale to T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2626923789","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626923789?lang=en_us&edition=fundamental","pubTime":"2026-04-09 00:16","pubTimestamp":1775665016,"startTime":"0","endTime":"0","summary":"TDS annual report for 2025 detailed a strategic reset following sale of UScellular wireless business and certain spectrum assets to T-Mobile, shifting focus to fiber broadband at TDS Telecom and tower leasing at Array Digital Infrastructure.Transaction closed Aug. 1, 2025 with final proceeds of USD 4.3 billion; Array issued a USD 23 per-share special dividend.TDS Telecom highlighted accelerated fiber buildout, topping 1 million marketable fiber addresses in September; long-term target raised to 2.1 million fiber service addresses.Array reported early progress as standalone tower company with more than 4,400 towers; T-Mobile signed a 15-year master lease covering 2,015 new tower sites.Management changes included Ken Dixon joining TDS Telecom in June; Anthony Carlson appointed to lead Array in November.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL13wNtL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035773651.USD","LU1983260115.SGD","LU0320765489.SGD","LU1621767737.EUR","LU1621767810.EUR","LU0077335932.USD","LU1066051811.HKD","BK4533","LU2264538146.SGD","LU2361044865.SGD","LU1267930573.SGD","LU0048573561.USD","BK4549","LU1303367103.USD","IE00BMPRXN33.USD","AD","LU1064131342.USD","LU0640476718.USD","IE00BMPRXQ63.HKD","LU1988902786.USD","LU2210149790.SGD","LU0314106906.USD","LU1621768206.USD","LU1066051225.USD","BK4585","BK4515","LU0276348264.USD","LU2361044949.HKD","LU0170899867.USD","LU0708994859.HKD","LU2361045086.USD","LU0267386448.USD","LU0251131958.USD","BK4561","TDS","LU1066051498.USD","IE00B775SV38.USD","LU0208291251.USD","LU0642271901.SGD","BK4588","LU1621768115.EUR","LU1280957306.USD","LU2098885051.SGD","LU2317271919.USD","IE00B3S45H60.SGD","LU0127658192.USD","LU0029864427.USD","LU2384288077.EUR","TMUS","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625911242","title":"Digitus Group Signs Agreement To Acquire Gulfsat Kuwait","url":"https://stock-news.laohu8.com/highlight/detail?id=2625911242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625911242?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:01","pubTimestamp":1775638860,"startTime":"0","endTime":"0","summary":"April 8 (Reuters) - DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS ::*DIGITUS GROUP - SIGNS AGREEMENT TO ACQUIRE GULFSAT KUWAIT*DIGITUS GROUP - TOTAL DEAL VALUE KD 6 MILLION*F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nRSD1NjBg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625592489","title":"Array Digital Infrastructure announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625592489","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625592489?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:35","pubTimestamp":1775572505,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure schedules annual shareholder meeting in Chicago on May 19, 2026.Shareholders will vote on election of nine directors, including three nominees elected by common shareholders.Meeting agenda also includes charter amendment to add officer exculpation provisions.Shareholders will cast advisory vote on 2025 executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL3NDW7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625959242","title":"Array Digital Infrastructure publishes 2025 annual report after wireless divestiture transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625959242?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:34","pubTimestamp":1775572497,"startTime":"0","endTime":"0","summary":"Array annual report for fiscal 2025 highlighted shift from UScellular wireless carrier to tower company, following divestiture of wireless operations to T-Mobile on Aug. 1, 2025.Company positioned as fifth-largest US tower operator, supported by more than 4,400 towers, retained wireless spectrum, noncontrolling investment interests.T-Mobile anchor deal set 15-year master lease covering 2,015 new tower sites, extending terms on about 600 existing sites.Sales and intake operations moved in-house, driving 47% rise in colocation applications, excluding impact of T-Mobile master lease.Spectrum monetization advanced with agreements covering 70% of holdings, including USD 4.3 billion transaction with T-Mobile in August 2025; remaining 30% largely C-Band spectrum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL4WWGJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1621767810.EUR","LU1621767737.EUR","IE00BMPRXN33.USD","LU0208291251.USD","LU0070302665.USD","LU1267930573.SGD","IE00BMPRXQ63.HKD","LU1316542783.SGD","LU1621768206.USD","LU1988902786.USD","LU0708994859.HKD","LU2317271919.USD","IE00BMPRXR70.SGD","BK4549","LU0029864427.USD","LU1506573853.SGD","LU2361044865.SGD","LU2361045086.USD","BK4533","IE00B775SV38.USD","LU0267386448.USD","LU1303367103.USD","LU2095319765.USD","BK4588","LU0640476718.USD","LU1069347547.HKD","LU0310800379.SGD","TMUS","GB00BDT5M118.USD","LU0786609619.USD","LU1064131342.USD","LU0320765489.SGD","LU2098885051.SGD","LU1983260115.SGD","LU1066051498.USD","LU0314106906.USD","LU2361044949.HKD","LU0077335932.USD","LU0061474705.USD","LU2210150020.SGD","LU0742534661.SGD","TDS","BK4561","LU0048573561.USD","AD","LU0128525929.USD","LU1621768115.EUR","LU0276348264.USD","BK4559","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625328769","title":"Press Release: AC Immune Announces Amendment to Morphomer (R) Tau License and Collaboration Agreement with Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2625328769","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625328769?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559600,"startTime":"0","endTime":"0","summary":"-- Amended agreement reflects growing excitement in the field for targeting. intracellular Tau and significant progress made with our Morphomer small. -- Investigational New Drug -enabling studies to commence in H1 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"The progress in this collaboration highlights the important breakthroughs we have made with Morphomer small molecules for intracellular targeting of Tau. We look forward to working with the team at Lilly to drive forward the development of these potentially disruptive small molecule therapeutics for early-stage treatment and long-term prevention of neurodegenerative diseases. Increasingly, the scientific evidence suggests that targeting intracellular Tau can slow or even completely halt the pathology. This collaboration exemplifies our work towards precision prevention of neurodegenerative diseases. We expect to initiate Investigational New Drug -enabling studies imminently.\". AC Immune SA is a clinical-stage biophar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4022","ACIU","BK4139","IND","R","BK4132","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624753639","title":"RBC Capital Keeps Their Buy Rating on Array Digital Infrastructure (AD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624753639","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624753639?lang=en_us&edition=fundamental","pubTime":"2026-04-03 09:47","pubTimestamp":1775180876,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Jonathan Atkin maintained a Buy rating on Array Digital Infrastructure on April 1 and set a price target of $54.00. The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-array-digital-infrastructure-ad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-array-digital-infrastructure-ad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624260555","title":"Blockchain Digital Infrastructure FY25 net loss narrows to $0.8 million; revenue falls 19% to $19 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624260555","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624260555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:47","pubTimestamp":1774993671,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure posted a net loss of USD 0.8 million for fiscal 2025.Revenue fell 19% to USD 19 million on a shift in customer mix and standstill agreements that capped energy usage and curtailed credits.Adjusted EBITDA slid 74% to USD 1.7 million.Cash from operations dropped to USD 2.3 million, leaving cash at USD 15,265 at year-end.Company expects One Blockchain South Carolina facility to expand from 40 MW to 50 MW, pending a new electric service agreement, and is developing a 25 MW AI-focused Minnesota site.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blockchain Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4VFLrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","AIB","BK4023","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624676537","title":"Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624676537","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624676537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"-- Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD --. -- Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD --. -- Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 --. -- Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 --. SAN DIEGO, March 31, 2026  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623584887","title":"Annovis Publishes Historical Review of Buntanetap in The Scientist","url":"https://stock-news.laohu8.com/highlight/detail?id=2623584887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623584887?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265424/0/en/Annovis-Publishes-Historical-Review-of-Buntanetap-in-The-Scientist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","LU1169589451.USD","LU1169590202.USD","BK4023","ANVS","BK4139","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623206803","title":"Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?","url":"https://stock-news.laohu8.com/highlight/detail?id=2623206803","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623206803?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:09","pubTimestamp":1774908562,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics recently reported positive 52-week Phase 2 APEX trial data for its lead anti-IL-13 antibody zumilokibart in moderate-to-severe atopic dermatitis, alongside completing a follow-on common stock offering of about US$403,000,000 at US$70 per share.\nThe maintenance data suggest zumilokibart may offer durable disease control with 3- or 6-month dosing intervals, a dosing schedule that could meaningfully differentiate it from existing atopic dermatitis treatments if later-stage...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/should-apogee-therapeutics-apge-infrequent-dosing-ad-data-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apge/apogee-therapeutics/news/should-apogee-therapeutics-apge-infrequent-dosing-ad-data-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4132","BK4215","APGE","LU0053671581.USD","BK4588","AD","BK4585","BK4139","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623432640","title":"Press Release: INmune Bio Inc. Announces 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623432640","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623432640?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:00","pubTimestamp":1774900800,"startTime":"0","endTime":"0","summary":"BOCA RATON, Fla., March 30, 2026  -- INmune Bio Inc.  , a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update.-- The CORDStrom program in recessive dystrophic epidermolysis bullosa.  is on target to file an MAA submission in the UK mid-summer,followed shortly thereafter by anticipated EMA and FDA regulatory. -- Hosted KOL led webinar focused on the latest results from the MissionEB. Phase III clinical trial highlighting the systemic disease-modifying. -- Announced the publishing of an overview of future applications and. research areas for mesenchymal stromal cell  therapies in the. -- Reported new Phase 2 imaging data at the 18th Clinical Trials on. Alzheimer's Disease conference , in San Diego, CA. Additional brain. imaging analyses are ongoing and expected to be reported in the near. -- Announced FDA alignment to advance to an adaptive Phase 2b/3. early Alzh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4575","BK4585","BK4132","BK4604","R","BK4555","INMB","TM","BK4588","03160","BK4139","BK4099","MAA","BK4150","BK4022","BK4215","MSC","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623114593","title":"Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623114593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623114593?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:01","pubTimestamp":1774868460,"startTime":"0","endTime":"0","summary":"– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with nearmaximal responses achieved in ~90% of patients – –Rademikibart was well tolerated with safet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264498/0/en/Rademikibart-Demonstrates-Best-in-Class-Potential-in-Phase-3-Atopic-Dermatitis-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}